Latest posts
-
6 Ace Investor Stocks That Are Trading at a Discount of Up to 78% Below Their 52-Week High
Ace investors are known for building portfolios across different companies and sectors. However, some stocks in their portfolios can also face sharp declines due to market conditions, company performance, or changes in investor sentiment. As a result, certain holdings may be trading well below their recent highs. In this article, we look at six stocks…
-
9 large-cap stocks that surged over 50% in the first half of FY27
Among these, we highlight 9 large-cap stocks that have surged over 50% in the first half of FY27 so far, significantly outperforming the benchmark. (Data Source: ACE Equity)
-
9 large-cap stocks that surged over 50% in the first half of FY27
Among these, we highlight 9 large-cap stocks that have surged over 50% in the first half of FY27 so far, significantly outperforming the benchmark. (Data Source: ACE Equity)
-
Quant Mutual Fund says investors should stay agile in portfolio allocation amid market shifts
The fund house noted that the geopolitical crisis in the Middle East had entered its eighth month and resulted in severe disruptions to global commodity supplies, with Brent crude rising above $100 a barrel.
-
Gold and silver price today, Oct 3: Check retail rates of 24K, 22K gold and 999 silver in your city ahead of Durga Puja
Gold and silver prices remained stable on October 3 in India, with slight fluctuations in both 24 and 22-karat gold rates. The MCX was closed, and gold traded above ₹1.49 lakh, with silver prices reaching ₹226,590/kg according to the IBA.
-
33.6% PAT CAGR vs 17.6% Revenue CAGR: Can Emcure Pharmaceuticals’ Margins Continue to Expand?
Emcure Pharmaceuticals is entering a phase where earnings are growing faster than revenue, supported by improving operating efficiency and scale. Between FY24 and FY26, PAT grew significantly faster than the topline, while margins also expanded. The key question is whether this operating leverage can continue as the company scales its domestic and international businesses. Emcure Pharmaceuticals…
-
Jio Platforms IPO may open on October 21, issue estimated at $3.8 billion: Report
The IPO is expected to remain open until October 23, with the anchor book likely to open on October 19. The shares are targeted to list on the stock exchanges on October 28, although the timeline remains subject to market conditions and could change depending on developments in financial markets, the report added.
-
IPO Calendar: Quiet week ahead after Rs 39,000 crore September rush, but Street to see 29 listings
The momentum had picked up sharply from August, after a muted first four months of FY27, as stronger listing gains and steady liquidity pulled investors back into new issues.
-
Bonus issues & stock split: 5 stocks rewarding shareholders this week
The list remains tentative as more companies may announce record dates for bonus issues and stock splits during the week.
-
More than half of mid-to-large cap companies fail to deliver returns in 2026
More than half of India’s mid-to-large tier companies with market capitalisation above ₹1,000 crore have faced losses in 2026. Eight companies have experienced significant market cap erosion, affecting investor sentiment. Factors such as regulatory issues, funding costs, and margin pressures contributed to these declines. Foreign portfolio investors have sold a substantial amount of Indian equities…